Atorvastatin: Difference between revisions

Jump to navigation Jump to search
Line 35: Line 35:
Atorvastatin is a selective, competitive inhibitor of [[HMG-CoA reductase]], the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to [[mevalonate]], a precursor of [[cholesterol]].  
Atorvastatin is a selective, competitive inhibitor of [[HMG-CoA reductase]], the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to [[mevalonate]], a precursor of [[cholesterol]].  


In animal models, atorvastatin lowers plasma cholesterol and [[lipoprotein]] levels by inhibiting [[HMG-CoA reductase]] and [[cholesterol]] synthesis in the liver and by increasing the number of hepatic [[LDL receptor]]s on the cell surface to enhance uptake and catabolism of LDL; atorvastatin also reduces [[LDL]] production and the number of [[LDL]] particles. Atorvastatin reduces [[LDL]]-C in some patients with homozygous [[familial hypercholesterolemia]] (FH), a population that rarely responds to other lipid-lowering medication(s).
In animal models, atorvastatin lowers plasma cholesterol and [[lipoprotein]] levels by inhibiting [[HMG-CoA reductase]] and [[cholesterol]] synthesis in the liver and by increasing the number of hepatic [[LDL receptor]]s on the cell surface to enhance uptake and catabolism of LDL; atorvastatin also reduces [[LDL]] production and the number of [[LDL]] particles<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = LIPITOR (ATORVASTATIN CALCIUM) TABLET, FILM COATED [PARKE-DAVIS DIV OF PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228#nlm34089-3 | publisher =  | date =  | accessdate = }}</ref>
 
Atorvastatin reduces total-C, [[LDL]]-C, and [[apo B]] in patients with homozygous and heterozygous FH, nonfamilial forms of [[hypercholesterolemia]], and mixed [[dyslipidemia]].
 
Atorvastatin also reduces [[VLDL]]-C and [[TG]] and produces variable increases in [[HDL]]-C and apolipoprotein A-1.
 
Atorvastatin reduces total-C, [[LDL]]-C, [[VLDL]]-C, [[apo B]], [[TG]], and non-[[HDL]]-C, and increases [[HDL]]-C in patients with isolated [[hypertriglyceridemia]].
 
Atorvastatin reduces intermediate density [[lipoprotein]] [[cholesterol]] ([[IDL]]-C) in patients with [[dysbetalipoproteinemia]].<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = LIPITOR (ATORVASTATIN CALCIUM) TABLET, FILM COATED [PARKE-DAVIS DIV OF PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228#nlm34089-3 | publisher =  | date =  | accessdate = }}</ref>


==References==
==References==
{{Reflist}}
{{Reflist}}

Revision as of 20:12, 30 January 2014

Atorvastatin
Lipitor® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]

For patient information, click here.

Overview

Atorvastatin is a member of the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents strokes through anti-inflammation and other mechanisms. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body.

Category

Lipid-Lowering Agents, Statins

US Brand Names

Lipitor®

FDA Package Insert

Indications and Usage | Dosage and Administration | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Description | Clinical Pharmacology | Clinical Studies | How Supplied/Storage and Handling | Labels and Packages

Mechanism of Action

Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of cholesterol.

In animal models, atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL; atorvastatin also reduces LDL production and the number of LDL particles[1]

References

  1. "LIPITOR (ATORVASTATIN CALCIUM) TABLET, FILM COATED [PARKE-DAVIS DIV OF PFIZER INC]".